Immunological differences between insect venom‐allergic patients with and without immunotherapy and asymptomatically sensitized subjects
Background Currently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable serological marker to monitor venom immunotherapy (VIT) does also not exist. Our aim was to find reliable serological markers to predict tol...
Saved in:
Published in | Allergy (Copenhagen) Vol. 73; no. 6; pp. 1223 - 1231 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Denmark
Blackwell Publishing Ltd
01.06.2018
|
Subjects | |
Online Access | Get full text |
ISSN | 0105-4538 1398-9995 1398-9995 |
DOI | 10.1111/all.13368 |
Cover
Loading…
Abstract | Background
Currently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable serological marker to monitor venom immunotherapy (VIT) does also not exist. Our aim was to find reliable serological markers to predict tolerance to bee and vespid stings.
Methods
We included 77 asymptomatically sensitized subjects, 85 allergic patients with acute systemic sting reactions, and 61 allergic patients currently treated with VIT. Levels of sIgE and sIgG4 to bee and vespid venom, rApi m 1, and rVes v 5 were measured immediately after allergic sting reactions or before sting challenges and 4 weeks later. All sting challenges were tolerated. The inhibitory activity was determined using BAT inhibition and ELIFAB assay.
Results
Median sIgG4 levels were 96‐fold higher in VIT patients (P < .001) while sIgE/sIgG4 ratios were consistently lower (P < .001). The ELIFAB assay was paralleled by low sIgE/sIgG4 ratios in VIT patients, showing markedly higher allergen‐blocking capacity (P < .001). An almost complete inhibition of the basophil response was seen in all patients treated with vespid venom, but not in those treated with bee venom. Four weeks after the sting, sIgE and sIgG4 levels were increased in allergic and asymptomatically sensitized patients, but not in VIT patients.
Conclusion
Immunological responses after stings varied in bee and vespid venom‐allergic patients. In patients under VIT, sIgE and sIgG4 remained completely stable after sting challenges. Monitoring VIT efficacy was only possible in vespid venom allergy, and the sIgG4 threshold for rVes v 5 had the highest sensitivity to confirm tolerance. The BAT inhibition test was the most reliable tool to confirm tolerance on an individual basis. |
---|---|
AbstractList | Currently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable serological marker to monitor venom immunotherapy (VIT) does also not exist. Our aim was to find reliable serological markers to predict tolerance to bee and vespid stings.BACKGROUNDCurrently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable serological marker to monitor venom immunotherapy (VIT) does also not exist. Our aim was to find reliable serological markers to predict tolerance to bee and vespid stings.We included 77 asymptomatically sensitized subjects, 85 allergic patients with acute systemic sting reactions, and 61 allergic patients currently treated with VIT. Levels of sIgE and sIgG4 to bee and vespid venom, rApi m 1, and rVes v 5 were measured immediately after allergic sting reactions or before sting challenges and 4 weeks later. All sting challenges were tolerated. The inhibitory activity was determined using BAT inhibition and ELIFAB assay.METHODSWe included 77 asymptomatically sensitized subjects, 85 allergic patients with acute systemic sting reactions, and 61 allergic patients currently treated with VIT. Levels of sIgE and sIgG4 to bee and vespid venom, rApi m 1, and rVes v 5 were measured immediately after allergic sting reactions or before sting challenges and 4 weeks later. All sting challenges were tolerated. The inhibitory activity was determined using BAT inhibition and ELIFAB assay.Median sIgG4 levels were 96-fold higher in VIT patients (P < .001) while sIgE/sIgG4 ratios were consistently lower (P < .001). The ELIFAB assay was paralleled by low sIgE/sIgG4 ratios in VIT patients, showing markedly higher allergen-blocking capacity (P < .001). An almost complete inhibition of the basophil response was seen in all patients treated with vespid venom, but not in those treated with bee venom. Four weeks after the sting, sIgE and sIgG4 levels were increased in allergic and asymptomatically sensitized patients, but not in VIT patients.RESULTSMedian sIgG4 levels were 96-fold higher in VIT patients (P < .001) while sIgE/sIgG4 ratios were consistently lower (P < .001). The ELIFAB assay was paralleled by low sIgE/sIgG4 ratios in VIT patients, showing markedly higher allergen-blocking capacity (P < .001). An almost complete inhibition of the basophil response was seen in all patients treated with vespid venom, but not in those treated with bee venom. Four weeks after the sting, sIgE and sIgG4 levels were increased in allergic and asymptomatically sensitized patients, but not in VIT patients.Immunological responses after stings varied in bee and vespid venom-allergic patients. In patients under VIT, sIgE and sIgG4 remained completely stable after sting challenges. Monitoring VIT efficacy was only possible in vespid venom allergy, and the sIgG4 threshold for rVes v 5 had the highest sensitivity to confirm tolerance. The BAT inhibition test was the most reliable tool to confirm tolerance on an individual basis.CONCLUSIONImmunological responses after stings varied in bee and vespid venom-allergic patients. In patients under VIT, sIgE and sIgG4 remained completely stable after sting challenges. Monitoring VIT efficacy was only possible in vespid venom allergy, and the sIgG4 threshold for rVes v 5 had the highest sensitivity to confirm tolerance. The BAT inhibition test was the most reliable tool to confirm tolerance on an individual basis. Currently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable serological marker to monitor venom immunotherapy (VIT) does also not exist. Our aim was to find reliable serological markers to predict tolerance to bee and vespid stings. We included 77 asymptomatically sensitized subjects, 85 allergic patients with acute systemic sting reactions, and 61 allergic patients currently treated with VIT. Levels of sIgE and sIgG to bee and vespid venom, rApi m 1, and rVes v 5 were measured immediately after allergic sting reactions or before sting challenges and 4 weeks later. All sting challenges were tolerated. The inhibitory activity was determined using BAT inhibition and ELIFAB assay. Median sIgG levels were 96-fold higher in VIT patients (P < .001) while sIgE/sIgG ratios were consistently lower (P < .001). The ELIFAB assay was paralleled by low sIgE/sIgG ratios in VIT patients, showing markedly higher allergen-blocking capacity (P < .001). An almost complete inhibition of the basophil response was seen in all patients treated with vespid venom, but not in those treated with bee venom. Four weeks after the sting, sIgE and sIgG levels were increased in allergic and asymptomatically sensitized patients, but not in VIT patients. Immunological responses after stings varied in bee and vespid venom-allergic patients. In patients under VIT, sIgE and sIgG remained completely stable after sting challenges. Monitoring VIT efficacy was only possible in vespid venom allergy, and the sIgG threshold for rVes v 5 had the highest sensitivity to confirm tolerance. The BAT inhibition test was the most reliable tool to confirm tolerance on an individual basis. BackgroundCurrently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable serological marker to monitor venom immunotherapy (VIT) does also not exist. Our aim was to find reliable serological markers to predict tolerance to bee and vespid stings.MethodsWe included 77 asymptomatically sensitized subjects, 85 allergic patients with acute systemic sting reactions, and 61 allergic patients currently treated with VIT. Levels of sIgE and sIgG4 to bee and vespid venom, rApi m 1, and rVes v 5 were measured immediately after allergic sting reactions or before sting challenges and 4 weeks later. All sting challenges were tolerated. The inhibitory activity was determined using BAT inhibition and ELIFAB assay.ResultsMedian sIgG4 levels were 96‐fold higher in VIT patients (P < .001) while sIgE/sIgG4 ratios were consistently lower (P < .001). The ELIFAB assay was paralleled by low sIgE/sIgG4 ratios in VIT patients, showing markedly higher allergen‐blocking capacity (P < .001). An almost complete inhibition of the basophil response was seen in all patients treated with vespid venom, but not in those treated with bee venom. Four weeks after the sting, sIgE and sIgG4 levels were increased in allergic and asymptomatically sensitized patients, but not in VIT patients.ConclusionImmunological responses after stings varied in bee and vespid venom‐allergic patients. In patients under VIT, sIgE and sIgG4 remained completely stable after sting challenges. Monitoring VIT efficacy was only possible in vespid venom allergy, and the sIgG4 threshold for rVes v 5 had the highest sensitivity to confirm tolerance. The BAT inhibition test was the most reliable tool to confirm tolerance on an individual basis. Background Currently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable serological marker to monitor venom immunotherapy (VIT) does also not exist. Our aim was to find reliable serological markers to predict tolerance to bee and vespid stings. Methods We included 77 asymptomatically sensitized subjects, 85 allergic patients with acute systemic sting reactions, and 61 allergic patients currently treated with VIT. Levels of sIgE and sIgG4 to bee and vespid venom, rApi m 1, and rVes v 5 were measured immediately after allergic sting reactions or before sting challenges and 4 weeks later. All sting challenges were tolerated. The inhibitory activity was determined using BAT inhibition and ELIFAB assay. Results Median sIgG4 levels were 96‐fold higher in VIT patients (P < .001) while sIgE/sIgG4 ratios were consistently lower (P < .001). The ELIFAB assay was paralleled by low sIgE/sIgG4 ratios in VIT patients, showing markedly higher allergen‐blocking capacity (P < .001). An almost complete inhibition of the basophil response was seen in all patients treated with vespid venom, but not in those treated with bee venom. Four weeks after the sting, sIgE and sIgG4 levels were increased in allergic and asymptomatically sensitized patients, but not in VIT patients. Conclusion Immunological responses after stings varied in bee and vespid venom‐allergic patients. In patients under VIT, sIgE and sIgG4 remained completely stable after sting challenges. Monitoring VIT efficacy was only possible in vespid venom allergy, and the sIgG4 threshold for rVes v 5 had the highest sensitivity to confirm tolerance. The BAT inhibition test was the most reliable tool to confirm tolerance on an individual basis. |
Author | Laipold, K. Herzog, S. A. Vollmann, J. Möbs, C. Sturm, G. J. Schrautzer, C. Arzt, L. Reider, N. Bohle, B. Pfützner, W. Bokanovic, D. Aberer, W. |
Author_xml | – sequence: 1 givenname: L. orcidid: 0000-0002-5489-2070 surname: Arzt fullname: Arzt, L. organization: Medical University of Graz – sequence: 2 givenname: D. surname: Bokanovic fullname: Bokanovic, D. organization: Medical University of Graz – sequence: 3 givenname: C. surname: Schrautzer fullname: Schrautzer, C. organization: Medical University of Graz – sequence: 4 givenname: K. surname: Laipold fullname: Laipold, K. organization: Medical University of Graz – sequence: 5 givenname: C. surname: Möbs fullname: Möbs, C. organization: Philipps‐University of Marburg – sequence: 6 givenname: W. surname: Pfützner fullname: Pfützner, W. organization: Philipps‐University of Marburg – sequence: 7 givenname: S. A. surname: Herzog fullname: Herzog, S. A. organization: Medical University of Graz – sequence: 8 givenname: J. surname: Vollmann fullname: Vollmann, J. organization: University of Graz – sequence: 9 givenname: N. surname: Reider fullname: Reider, N. organization: Medical University of Innsbruck – sequence: 10 givenname: B. orcidid: 0000-0002-5105-7985 surname: Bohle fullname: Bohle, B. organization: Medical University of Vienna – sequence: 11 givenname: W. surname: Aberer fullname: Aberer, W. organization: Medical University of Graz – sequence: 12 givenname: G. J. surname: Sturm fullname: Sturm, G. J. email: gunter.sturm@medunigraz.at organization: Medical University of Graz |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29171032$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kc1u3CAUhVGVqpmkXfQFKqRu2oUTsLExyyjqT6SRuskeMfjSMMLgAu7IWXXdVZ4xT1I6M9lELRuQ-M45cO4ZOvHBA0JvKbmgZV0q5y5o03T9C7SijegrIUR7glaEkrZibdOforOUtoQQXgvyCp3WgnJKmnqFft-M4-yDC9-tVg4P1hiI4DUkvIG8A_DY-gQ645_gw_j466GEQSw0nlS24HPCO5vvsPLD_hDmjO3eM99BVNOyv1FpGaccxiIpMW7BCXyy2d7DgNO82ZaA9Bq9NMoleHPcz9Ht50-311-r9bcvN9dX60o35SsVcMqA1wMzbNCt2Whd605xwZVpddf2olc9bwwXoFnf0YFTTTmjAxOtgM405-jDwXaK4ccMKcvRJg3OKQ9hTpKKrmesbvq2oO-fodswR18eJ2vS0k5QVotCvTtS82aEQU7Rjiou8qnkAlweAB1DShGM1DaXJoLPUVknKZF_xyhLMXI_xqL4-EzxZPov9ui-sw6W_4Pyar0-KP4AunOwdw |
CitedBy_id | crossref_primary_10_1016_j_reval_2021_01_006 crossref_primary_10_1111_pai_13189 crossref_primary_10_21508_1027_4065_2024_69_4_102_108 crossref_primary_10_1007_s00060_018_5737_2 crossref_primary_10_3389_fimmu_2020_01815 crossref_primary_10_1186_s13223_020_0416_4 crossref_primary_10_1097_01_JAA_0000758196_47706_91 crossref_primary_10_1111_all_14747 crossref_primary_10_1111_cea_13237 crossref_primary_10_3390_vaccines9030249 crossref_primary_10_1007_s15007_020_0745_0 crossref_primary_10_1016_j_alit_2020_08_002 crossref_primary_10_1097_ACI_0000000000000580 crossref_primary_10_2217_imt_2020_0326 crossref_primary_10_29262_ram_v69i3_1135 crossref_primary_10_1111_pai_13854 crossref_primary_10_1186_s13223_020_00427_z crossref_primary_10_1007_s15007_018_1648_1 crossref_primary_10_1111_all_13980 crossref_primary_10_1007_s40629_020_00117_7 crossref_primary_10_1016_j_jaip_2024_10_029 crossref_primary_10_1111_cea_13305 crossref_primary_10_1016_j_jaip_2019_06_008 crossref_primary_10_1007_s00103_020_03224_6 crossref_primary_10_1097_ACI_0000000000000693 crossref_primary_10_3389_fimmu_2018_03131 |
Cites_doi | 10.1111/j.1398-9995.2004.00505.x 10.1111/j.1398-9995.1996.tb04632.x 10.1186/1471-2105-12-77 10.1067/mai.2002.129124 10.1016/S0140-6736(77)91953-5 10.1016/j.jaci.2014.09.049 10.1371/journal.pone.0020842 10.1159/000161586 10.1016/0091-6749(91)90095-6 10.1371/journal.pone.0146021 10.1016/j.jaci.2016.04.024 10.1067/mai.2001.120013 10.1016/0091-6749(79)90075-7 10.1016/j.jaci.2012.07.056 10.1111/all.12606 10.1016/0091-6749(83)90503-1 10.1016/S0091-6749(98)70167-8 10.1016/j.jaci.2013.05.025 10.1111/j.1398-9995.1994.tb02660.x 10.1111/j.1398-9995.2004.00400.x 10.1111/j.1365-2222.1993.tb01791.x 10.1111/j.1398-9995.1996.tb00110.x 10.1016/j.jaci.2012.05.047 10.1016/j.jaci.2013.10.046 10.1016/S0091-6749(00)90092-7 10.1111/all.13154 10.1111/j.1398-9995.2012.02817.x 10.1111/j.1398-9995.1996.tb04596.x 10.1016/j.jaci.2011.12.975 10.1046/j.1365-2222.1998.00411.x 10.1111/j.1365-2222.1986.tb01963.x 10.1111/j.1365-2222.2009.03303.x 10.1111/j.1398-9995.2011.02745.x 10.1016/S0091-6749(05)80019-3 10.1016/S0091-6749(97)70271-9 10.1016/j.jaci.2013.10.060 10.1046/j.1365-2222.2000.00863.x 10.1111/j.1398-9995.1989.tb04172.x 10.1007/s12026-009-8160-3 10.1111/all.12568 |
ContentType | Journal Article |
Copyright | 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. Copyright © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd |
Copyright_xml | – notice: 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. – notice: Copyright © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 K9. 7X8 |
DOI | 10.1111/all.13368 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1398-9995 |
EndPage | 1231 |
ExternalDocumentID | 29171032 10_1111_all_13368 ALL13368 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 23M 2WC 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8F7 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAKAS AAMMB AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFNX AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHEFC AHMBA AIACR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOETA ATUGU AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EJD EMOBN EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D P6G PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI TR2 UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WVDHM WXI WXSBR XG1 Y6R ZGI ZXP ZZTAW ~IA ~KM ~WT AAHHS AAYXX ACCFJ AEEZP AEQDE AIWBW AJBDE CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 K9. 7X8 |
ID | FETCH-LOGICAL-c3538-e714e72d4f4dc5fbcc2c6a797af5c65898a873f79ec4861d71c1741d4959e6f3 |
IEDL.DBID | DR2 |
ISSN | 0105-4538 1398-9995 |
IngestDate | Fri Jul 11 00:31:30 EDT 2025 Fri Jul 25 09:24:24 EDT 2025 Thu Apr 03 07:05:02 EDT 2025 Tue Jul 01 04:15:06 EDT 2025 Thu Apr 24 23:12:06 EDT 2025 Wed Aug 20 07:25:54 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | IgG4 basophil activation test hymenoptera venom allergy venom immunotherapy IgE |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3538-e714e72d4f4dc5fbcc2c6a797af5c65898a873f79ec4861d71c1741d4959e6f3 |
Notes | Funding information This study was supported by a research grant from the Philipps‐University Marburg to C.M ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-5105-7985 0000-0002-5489-2070 |
PMID | 29171032 |
PQID | 2051691429 |
PQPubID | 34098 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_1968442385 proquest_journals_2051691429 pubmed_primary_29171032 crossref_citationtrail_10_1111_all_13368 crossref_primary_10_1111_all_13368 wiley_primary_10_1111_all_13368_ALL13368 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | June 2018 2018-06-00 2018-Jun 20180601 |
PublicationDateYYYYMMDD | 2018-06-01 |
PublicationDate_xml | – month: 06 year: 2018 text: June 2018 |
PublicationDecade | 2010 |
PublicationPlace | Denmark |
PublicationPlace_xml | – name: Denmark – name: Zurich |
PublicationTitle | Allergy (Copenhagen) |
PublicationTitleAlternate | Allergy |
PublicationYear | 2018 |
Publisher | Blackwell Publishing Ltd |
Publisher_xml | – name: Blackwell Publishing Ltd |
References | 1993; 23 1998; 28 1989; 44 2002; 110 2015; 70 2015; 10 1986; 16 1996; 51 2014; 24 1994; 49 2008; 148 1983; 72 2011; 12 2001; 108 2014; 133 2011; 6 2012; 129 1992; 90 2017; 72 2012; 130 2010; 47 2015; 135 2000; 105 1991; 88 2004; 59 2000; 30 1997; 100 1977; 1 2016; 138 2013; 132 1979; 64 2012; 67 1998; 101 2009; 39 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 Hayashi Y (e_1_2_8_31_1) 2014; 24 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_21_1 e_1_2_8_42_1 e_1_2_8_22_1 e_1_2_8_23_1 e_1_2_8_41_1 e_1_2_8_40_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_39_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_16_1 e_1_2_8_37_1 e_1_2_8_32_1 e_1_2_8_10_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_30_1 |
References_xml | – volume: 23 start-page: 647 year: 1993 end-page: 660 article-title: Venom‐specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings publication-title: Clin Exp Allergy – volume: 133 start-page: 1383 year: 2014 end-page: 1389 article-title: Component resolution reveals additional major allergens in patients with honeybee venom allergy publication-title: J Allergy Clin Immunol – volume: 30 start-page: 1166 year: 2000 end-page: 1171 article-title: Diagnosis of venom allergy by flow cytometry. Correlation with clinical history, skin tests, specific IgE, histamine and leukotriene C4 release publication-title: Clin Exp Allergy – volume: 133 start-page: 1635 year: 2014 end-page: 1643 article-title: Sensitization to Hymenoptera venoms is common, but systemic sting reactions are rare publication-title: J Allergy Clin Immunol – volume: 49 start-page: 272 year: 1994 end-page: 280 article-title: A comparative study of IgG subclass antibodies in patients allergic to wasp or bee venom publication-title: Allergy – volume: 59 start-page: 1110 year: 2004 end-page: 1117 article-title: The CD63 basophil activation test in Hymenoptera venom allergy: a prospective study publication-title: Allergy – volume: 72 start-page: 1419 year: 2017 end-page: 1422 article-title: Questionable diagnostic benefit of the commercially available panel of bee venom components publication-title: Allergy – volume: 72 start-page: 376 year: 1983 end-page: 385 article-title: Antibodies to purified bee venom proteins and peptides. II. A detailed study of changes in IgE and IgG antibodies to individual bee venom antigens publication-title: J Allergy Clin Immunol – volume: 47 start-page: 273 year: 2010 end-page: 284 article-title: IgE antibody‐specific activity in human allergic disease publication-title: Immunol Res – volume: 44 start-page: 412 year: 1989 end-page: 418 article-title: Predictive value of venom‐specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom publication-title: Allergy – volume: 6 start-page: e20842 year: 2011 article-title: Inconsistent Results of Diagnostic Tools Hamper the Differentiation between Bee and Vespid Venom Allergy publication-title: PLoS One – volume: 138 start-page: 1663 year: 2016 end-page: 1671 article-title: Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venom immunotherapy publication-title: J Allergy Clin Immunol – volume: 67 start-page: 217 year: 2012 end-page: 226 article-title: Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy publication-title: Allergy – volume: 67 start-page: 822 year: 2012 end-page: 830 article-title: Basophil response and the induction of a tolerance in venom immunotherapy: a long‐term sting challenge study publication-title: Allergy – volume: 51 start-page: 216 year: 1996 end-page: 225 article-title: The sting challenge test in Hymenoptera venom allergy. Position paper of the Subcommittee on Insect Venom Allergy of the European Academy of Allergology and Clinical Immunology publication-title: Allergy – volume: 59 start-page: 589 year: 2004 end-page: 595 article-title: Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations publication-title: Allergy – volume: 148 start-page: 261 year: 2008 end-page: 264 article-title: Asymptomatic Sensitization to Hymenoptera Venom Is Related to Total Immunoglobulin E Levels publication-title: Int Arch Allergy Immunol – volume: 129 start-page: 1406 year: 2012 end-page: 1408 article-title: High sensitivity of CAP‐FEIA rVes v 5 and rVes v 1 for diagnosis of Vespula venom allergy publication-title: J Allergy Clin Immunol – volume: 16 start-page: 317 year: 1986 end-page: 322 article-title: Sub‐class of IgG anti‐bee venom antibody produced during bee venom immunotherapy and its relationship to long‐term protection from bee stings and following termination of venom immunotherapy publication-title: Clin Allergy – volume: 51 start-page: 372 year: 1996 end-page: 377 article-title: IgE antibodies to Hymenoptera venoms in the serum are common in the general population and are related to indications of atopy publication-title: Allergy – volume: 110 start-page: 928 year: 2002 end-page: 933 article-title: Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high‐risk patients publication-title: J Allergy Clin Immunol – volume: 28 start-page: 1292 year: 1998 end-page: 1298 article-title: Bee sting allergy in beekeepers publication-title: Clin Exp Allergy – volume: 100 start-page: 767 year: 1997 end-page: 770 article-title: Discontinuation of yellow jacket venom immunotherapy: follow‐up of 75 patients by means of deliberate sting challenge publication-title: J Allergy Clin Immunol – volume: 12 start-page: 77 year: 2011 article-title: pROC: an open‐source package for R and S+ to analyze and compare ROC curves publication-title: BMC Bioinformatics – volume: 90 start-page: 386 year: 1992 end-page: 393 article-title: Clinical correlation of the venom‐specific IgG antibody level during maintenance venom immunotherapy publication-title: J Allergy Clin Immunol – volume: 88 start-page: 339 year: 1991 end-page: 348 article-title: Clinical and immunologic follow‐up of patients who stop venom immunotherapy publication-title: J Allergy Clin Immunol – volume: 132 start-page: 1003 year: 2013 end-page: 1005 article-title: Cell‐free detection of allergen‐IgE cross‐linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy publication-title: J Allergy Clin Immunol – volume: 108 start-page: 1045 year: 2001 end-page: 1052 article-title: Antibody binding to venom carbohydrates is a frequent cause for double positivity to honeybee and yellow jacket venom in patients with stinging‐insect allergy publication-title: J Allergy Clin Immunol – volume: 70 start-page: 457 year: 2015 end-page: 460 article-title: Comparable profiles of serum histamine and IgG4 levels in allergic beekeepers publication-title: Allergy – volume: 70 start-page: 715 year: 2015 end-page: 719 article-title: Decline of Ves v 5‐specific blocking capacity in wasp venom‐allergic patients after stopping allergen immunotherapy publication-title: Allergy – volume: 64 start-page: 5 year: 1979 end-page: 12 article-title: Insect allergy: the state of the art publication-title: J Allergy Clin Immunol – volume: 1 start-page: 466 year: 1977 end-page: 469 article-title: Incidence and severity of anaphylactoid reactions to colloid volume substitutes publication-title: Lancet – volume: 24 start-page: 192 year: 2014 end-page: 194 article-title: Usefulness of specific‐IgG4 to Hymenoptera venom in the natural history of hymenoptera stings publication-title: J Investig Allergol Clin Immunol – volume: 105 start-page: 385 year: 2000 end-page: 390 article-title: Survey of patients after discontinuing venom immunotherapy publication-title: J Allergy Clin Immunol – volume: 39 start-page: 1353 year: 2009 end-page: 1357 article-title: Time course of serum inhibitory activity for facilitated allergen‐IgE binding during bee venom immunotherapy in children publication-title: Clin Exp Allergy – volume: 10 start-page: e0146021 year: 2015 article-title: Dose‐Response Analysis Using R publication-title: PLoS One – volume: 130 start-page: 817 year: 2012 article-title: Ves v 5 can establish the diagnosis in patients without detectable specific IgE to wasp venom and a possible north‐south difference in Api m 1 sensitization in Europe publication-title: J Allergy Clin Immunol – volume: 51 start-page: 540 year: 1996 end-page: 546 article-title: Honeybee venom allergy: immunoblot studies in allergic patients after immunotherapy and before sting challenge publication-title: Allergy – volume: 135 start-page: 913 year: 2015 end-page: 921 article-title: Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response publication-title: J Allergy Clin Immunol – volume: 101 start-page: 606 year: 1998 end-page: 612 article-title: Long‐term protection after stopping venom immunotherapy: results of re‐stings in 200 patients publication-title: J Allergy Clin Immunol – volume: 130 start-page: 1108 year: 2012 end-page: 1116 article-title: Birch pollen immunotherapy results in long‐term loss of Bet v 1‐specific TH2 responses, transient TR1 activation, and synthesis of IgE‐blocking antibodies publication-title: J Allergy Clin Immunol – ident: e_1_2_8_37_1 doi: 10.1111/j.1398-9995.2004.00505.x – ident: e_1_2_8_7_1 doi: 10.1111/j.1398-9995.1996.tb04632.x – volume: 24 start-page: 192 year: 2014 ident: e_1_2_8_31_1 article-title: Usefulness of specific‐IgG4 to Hymenoptera venom in the natural history of hymenoptera stings publication-title: J Investig Allergol Clin Immunol – ident: e_1_2_8_28_1 doi: 10.1186/1471-2105-12-77 – ident: e_1_2_8_12_1 doi: 10.1067/mai.2002.129124 – ident: e_1_2_8_23_1 doi: 10.1016/S0140-6736(77)91953-5 – ident: e_1_2_8_40_1 doi: 10.1016/j.jaci.2014.09.049 – ident: e_1_2_8_4_1 doi: 10.1371/journal.pone.0020842 – ident: e_1_2_8_8_1 doi: 10.1159/000161586 – ident: e_1_2_8_13_1 doi: 10.1016/0091-6749(91)90095-6 – ident: e_1_2_8_27_1 doi: 10.1371/journal.pone.0146021 – ident: e_1_2_8_34_1 doi: 10.1016/j.jaci.2016.04.024 – ident: e_1_2_8_10_1 doi: 10.1067/mai.2001.120013 – ident: e_1_2_8_16_1 doi: 10.1016/0091-6749(79)90075-7 – ident: e_1_2_8_5_1 doi: 10.1016/j.jaci.2012.07.056 – ident: e_1_2_8_26_1 doi: 10.1111/all.12606 – ident: e_1_2_8_17_1 doi: 10.1016/0091-6749(83)90503-1 – ident: e_1_2_8_32_1 doi: 10.1016/S0091-6749(98)70167-8 – ident: e_1_2_8_25_1 doi: 10.1016/j.jaci.2013.05.025 – ident: e_1_2_8_21_1 doi: 10.1111/j.1398-9995.1994.tb02660.x – ident: e_1_2_8_3_1 doi: 10.1111/j.1398-9995.2004.00400.x – ident: e_1_2_8_19_1 doi: 10.1111/j.1365-2222.1993.tb01791.x – ident: e_1_2_8_22_1 doi: 10.1111/j.1398-9995.1996.tb00110.x – ident: e_1_2_8_42_1 doi: 10.1016/j.jaci.2012.05.047 – ident: e_1_2_8_9_1 doi: 10.1016/j.jaci.2013.10.046 – ident: e_1_2_8_11_1 doi: 10.1016/S0091-6749(00)90092-7 – ident: e_1_2_8_33_1 doi: 10.1111/all.13154 – ident: e_1_2_8_14_1 doi: 10.1111/j.1398-9995.2012.02817.x – ident: e_1_2_8_15_1 doi: 10.1111/j.1398-9995.1996.tb04596.x – ident: e_1_2_8_35_1 doi: 10.1016/j.jaci.2011.12.975 – ident: e_1_2_8_29_1 doi: 10.1046/j.1365-2222.1998.00411.x – ident: e_1_2_8_36_1 doi: 10.1111/j.1365-2222.1986.tb01963.x – ident: e_1_2_8_39_1 doi: 10.1111/j.1365-2222.2009.03303.x – ident: e_1_2_8_6_1 doi: 10.1111/j.1398-9995.2011.02745.x – ident: e_1_2_8_20_1 doi: 10.1016/S0091-6749(05)80019-3 – ident: e_1_2_8_38_1 doi: 10.1016/S0091-6749(97)70271-9 – ident: e_1_2_8_41_1 doi: 10.1016/j.jaci.2013.10.060 – ident: e_1_2_8_2_1 doi: 10.1046/j.1365-2222.2000.00863.x – ident: e_1_2_8_18_1 doi: 10.1111/j.1398-9995.1989.tb04172.x – ident: e_1_2_8_24_1 doi: 10.1007/s12026-009-8160-3 – ident: e_1_2_8_30_1 doi: 10.1111/all.12568 |
SSID | ssj0007290 |
Score | 2.3913274 |
Snippet | Background
Currently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable... Currently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable... BackgroundCurrently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1223 |
SubjectTerms | Adolescent Adult Aged Aged, 80 and over Allergens Allergens - immunology Allergies Antibody Specificity - immunology Arthropod Venoms - immunology Asymptomatic Diseases basophil activation test Bees Biological Variation, Population Female Humans hymenoptera venom allergy Hypersensitivity - diagnosis Hypersensitivity - etiology Hypersensitivity - therapy IgE IgG4 Immunoassay Immunoglobulin E Immunoglobulin E - blood Immunoglobulin E - immunology Immunoglobulin G - blood Immunoglobulin G - immunology Immunological tolerance Immunology Immunotherapy Insect Bites and Stings - complications Insect Bites and Stings - immunology Male Middle Aged Phenotype Sensitivity and Specificity Stings Venom venom immunotherapy Young Adult |
Title | Immunological differences between insect venom‐allergic patients with and without immunotherapy and asymptomatically sensitized subjects |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fall.13368 https://www.ncbi.nlm.nih.gov/pubmed/29171032 https://www.proquest.com/docview/2051691429 https://www.proquest.com/docview/1968442385 |
Volume | 73 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqHhAX3o-FggziwCUrkjixLU4Voiqo5YCK1ANS5Ke0YptUdXLYnjj31N_IL2HGcQLlISEukaU4tpN4xt-MZz4T8kKVlRLaMMxYVhmTOs-UqmTGKl1zI52XHv2Qhx_q_U_s_XF1vEVeT7kwIz_E7HBDyYj6GgVc6fCTkKv1egkGVo2JvhirhYDo4w_qKJ78K4AfoONSJFYhjOKZn7y6Fv0GMK_i1bjg7N0kn6ehjnEmX5ZDr5fm_BcWx_98l1vkRgKidHecObfJlmvvkGuHaav9Lrl4h5kjk2qk00EqoFZoiu2iqzaAuqSgLruTb18v8VSWM6hNE1droOjkpaq1sdANPV3FNsecr028o8Lm5LTvInEsNLChASPq-9W5szQMGr1E4R452nt79GY_Swc3ZKZEBep4zhwvLPPMmsprYwpTKy658pUByCOFErz0XDrDRJ1bnhswjHILxpp0tS_vk-22a91DQq2VtpA8VwCjGPdK5Z5rK-Cam8IrtiAvpz_YmERqjmdrrJvJuIGhN_HTLsjzuerpyOTxp0o70zRokjCHpniFm4k5rNwL8my-DWKIeyuqdd0QGlBkggE0FdWCPBinz9xLASYx8hbCYOMk-Hv3ze7BQSw8-veqj8l1AHFiDF_bIdv92eCeAFDq9dMoEd8B9S0Thw |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgGX8qYLBQziwCWrJnFiW-JSIaot7PaAFqkXFDl-SCu2SdUkh-2JMyd-I7-EseMEykNCXCJLcWwn8Yy_GY-_AXgh00zyUlF3YllGVJRxJGUmIpqVOVPCWGGdH3JxnM8-0Lcn2ckWvBrOwvT8EKPDzUmG19dOwJ1D-icpl-v1FC2snF-Bqy6jtzeo3v8gj2LBw4IIArtOeeAVcnE846OXV6PfIOZlxOqXnMOb8HEYbB9p8mnateVUXfzC4_i_b3MLdgIWJQf95LkNW6a6A9cWYbf9Lnw5codHBu1IhlwqqFlICO8iq6pBjUlQY9an3z5_dYlZzrE2CXStDXF-XiIr7Qt115KVb7M_9rXxd2SzOT1ra88diw1sSOOC6tvVhdGk6UrnKGruwfLwzfL1LAq5GyKVOh1qWEwNSzS1VKvMlkolKpdMMGkzhahHcMlZapkwivI81ixWaBvFGu01YXKb3oftqq7MLhCthU4EiyUiKcqslLFlpeZ4jVViJZ3Ay-EXFirwmrv0GutisG9w6IX_tBN4PlY968k8_lRpb5gHRZDnpkj23X5ijIv3BJ6Nt1ES3faKrEzdNQXqMk4RnfJsAg_6-TP2kqBV7KgLcbB-Fvy9--JgPveFh_9e9Slcny0X82J-dPzuEdxATMf7aLY92G7PO_MYcVNbPvHi8R0IZxei |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlVceFMWChjEgUtWdeLEtjhVlFUL2wqhIvWAFDl-SCu2yapJDtsTZ078Rn4JY-cB5SEhLpGlOLaTzIy_GY8_AzxXSapEoZnfsawiJgsaKZXKiKVFxrW0Tjofhzw6zg4-sDen6ekGvBz2wnT8EGPAzWtGsNdewVfG_aTkarmcooOViStwlWW7wov0_vsf3FG8D7AggMCeE9HTCvk0nvHRy5PRbwjzMmANM87sBnwcxtolmnyatk0x1Re_0Dj-58vchOs9EiV7nejcgg1b3oato36t_Q58OfRbRwbbSIaTVNCukD65iyzKGu0lQXtZnX37_NUfy3KOtUlP1loTH-UlqjShULUNWYQ2u01f63BH1euzVVMF5lhsYE1qn1LfLC6sIXVb-DBRfRdOZq9PXh1E_ckNkU68BbWcMstjwxwzOnWF1rHOFJdcuVQj5pFCCZ44Lq1mIqOGU42eETXorUmbueQebJZVae8DMUaaWHKqEEcx7pSijhdG4JXq2Ck2gRfDH8x1z2ruD9dY5oN3g0PPw6edwLOx6qqj8vhTpZ1BDPJem-s83vWriRSn7gk8HW-jHvrFFVXaqq1ztGSCITYV6QS2O_EZe4nRJ_bEhTjYIAR_7z7fm89D4cG_V30CW-_2Z_n88PjtQ7iGgE50qWw7sNmct_YRgqameByU4zvdFxZa |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunological+differences+between+insect+venom-allergic+patients+with+and+without+immunotherapy+and+asymptomatically+sensitized+subjects&rft.jtitle=Allergy+%28Copenhagen%29&rft.au=Arzt%2C+L&rft.au=Bokanovic%2C+D&rft.au=Schrautzer%2C+C&rft.au=Laipold%2C+K&rft.date=2018-06-01&rft.issn=1398-9995&rft.eissn=1398-9995&rft.volume=73&rft.issue=6&rft.spage=1223&rft_id=info:doi/10.1111%2Fall.13368&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0105-4538&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0105-4538&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0105-4538&client=summon |